Latest Trastuzumab Stories
SAN DIEGO, Dec. 12, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
- Update on complete remissions with personalized cell therapy CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia EAST HANOVER, N.J., Dec.
WORCESTER, Mass. and TORONTO, Oct.
RnRMarketResearch.com adds “Perjeta & Kadcyla (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023” to its store.
DALLAS, October 22, 2014 /PRNewswire/ -- RnRMarketResearch.com adds PharmaPoint: HER2-Positive Breast Cancer - Drug Forecast and Market Analysis to 2023 research reports
ChinaMarketResearchReports.com adds Latest Report on “Global and China Monoclonal Antibody Industry Report, 2014-2019” to its store.
NORWALK, Conn., Oct.
Sales of Breast Cancer Therapies are Expected to Almost Double Through 2023, Fueled by Growth in Several Distinct Market Segments, According to Findings from Decision Resources Group BURLINGTON,
In the news release, The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 million by 2023, issued 18-Sep-2014 by Decision
Perjeta, a new breast cancer drug developed by Swiss pharmaceutical company Roche, has shown “unprecedented” success in extending the lives of patients in a clinical trial, according to research results released on Sunday.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.